BRCA and Ovarian Cancer: Risk, Screening, Prevention Options

BRCA1 and BRCA2 mutations create dramatically elevated ovarian cancer risk—up to 44% for BRCA1 carriers and 17% for BRCA2 carriers by age 80. These mutations impair DNA repair mechanisms, preventing normal cellular safeguards against cancer. BRCA carriers require specialized surveillance protocols and preventive interventions that reduce cancer mortality by 80-90%.

If you carry a BRCA mutation, understanding your risk, available screening options, and prevention strategies is crucial for taking control of your health. This comprehensive guide explores how BRCA mutations affect ovarian cancer risk, what medical evidence shows about screening effectiveness, and the full range of prevention options available today.

Understanding BRCA1/BRCA2 Ovarian Cancer Risk: Genetic Mechanisms

BRCA1 and BRCA2 mutations represent pathogenic variants in genes responsible for DNA repair, creating a fundamental vulnerability to cancer development. According to the National Cancer Institute (2024), these genes normally produce proteins that fix damaged DNA, protecting cells from becoming cancerous. When mutations compromise this protective function, ovarian cells accumulate genetic damage over time, leading to cancer development.

What Are BRCA Genes and How Do They Protect Against Cancer?

The BRCA proteins function as tumor suppressors, maintaining cellular integrity through homologous recombination repair (HRR)—a sophisticated DNA repair mechanism. When BRCA proteins work normally, they scan for DNA breaks and coordinate repair processes that restore genetic stability. This continuous surveillance prevents mutations from accumulating in ovarian cells, which face particular vulnerability due to high rates of cell division during the reproductive years.

Without functional BRCA proteins, cells cannot adequately repair DNA damage. Over time, additional mutations accumulate in ovarian tissue. This progressive genetic instability transforms normal cells into cancer cells. The process typically unfolds over decades, which explains why BRCA-associated cancers typically appear in mid-to-late adulthood rather than childhood.

The Two-Hit Hypothesis in BRCA-Associated Cancer

BRCA carriers inherit one mutated copy of the BRCA gene from a parent, while the other copy is initially normal. Cancer development requires a "second hit"—a somatic mutation occurring in an ovarian cell during a woman's lifetime. When this second mutation damages the remaining functional copy, that cell loses all BRCA protection and becomes vulnerable to malignant transformation.

Research published in Nature Genetics (2023) demonstrates that this two-hit mechanism explains why cancer risk increases with age. The longer tissues are exposed to potential mutations, the greater the probability that a second hit will occur in a critical cell. This molecular insight has profound implications: it explains both why BRCA carriers face dramatically elevated risk and why screening and surveillance become increasingly important with advancing age.

Risk Differences Between BRCA1 and BRCA2

BRCA1 carriers face substantially higher ovarian cancer risk compared to BRCA2 carriers. According to the NCBI GeneReviews (2024), BRCA1 mutations carry a 39-44% lifetime ovarian cancer risk by age 80, with median diagnosis around age 54. BRCA2 mutations confer an 11-17% lifetime risk with median diagnosis closer to age 62. This tenfold difference reflects distinct functional properties of the two genes and their varying roles in ovarian cell protection.

The mutation location within each gene also influences cancer risk. Certain BRCA1 mutations—particularly the founder mutations common in Ashkenazi Jewish ancestry (185delAG, 5382insC in BRCA1; 6174delT in BRCA2)—carry even higher penetrance. This genetic heterogeneity means that two individuals with BRCA mutations may face meaningfully different risk profiles based on the specific mutation location and family history patterns.

<!-- IMAGE: Risk Comparison Graph | Alt: Lifetime ovarian cancer risk comparison showing 1.4% in general population, 39-44% in BRCA1 carriers, and 11-17% in BRCA2 carriers by age 80 -->

How BRCA1/BRCA2 Ovarian Cancer Risk Impact Your Health

Clinical Presentation and Disease Characteristics

BRCA-associated ovarian cancers typically present with advanced-stage disease. Common symptoms at diagnosis include bloating, pelvic pain, early satiety (feeling full quickly), and abdominal distention—signs that often indicate stage III or IV cancer. The disease frequently develops 10-15 years earlier than sporadic ovarian cancer, compressing the window for prevention.

BRCA-related ovarian cancers show distinct clinical characteristics. They predominantly manifest as high-grade serous histology, the most aggressive ovarian cancer subtype. The five-year survival rate for BRCA-associated advanced ovarian cancer remains approximately 40-50% with treatment, compared to broader ovarian cancer survival rates of 30-40%. Importantly, BRCA-associated cancers demonstrate exceptional sensitivity to platinum-based chemotherapy and PARP inhibitors, offering treatment advantages that improve outcomes for diagnosed patients.

Psychological and Lifestyle Burden

Receiving a positive BRCA result creates unique psychological challenges beyond medical considerations. Women must navigate reproductive decision-making—timing pregnancies before potential preventive surgery, considering genetic counseling for offspring, and potentially using pre-implantation genetic diagnosis (PGD) to have BRCA-mutation-free children. These decisions carry emotional weight alongside complex medical implications.

The burden of surveillance or decision-making about surgery creates ongoing psychological stress. Some women experience anxiety about cancer risk despite negative screening results. Others struggle with the profound life decision of whether to undergo risk-reducing surgery with permanent effects on fertility and menopause timing. Professional psychological counseling and support groups become valuable resources, helping women process these complex choices alongside their healthcare teams.

Screening Options for BRCA Carriers

Ovarian Cancer Screening Methods

Screening for ovarian cancer in BRCA carriers employs several approaches, though effectiveness remains limited. The National Comprehensive Cancer Network (NCCN) recommends that BRCA carriers begin ovarian cancer surveillance at age 30-35 using combination screening: serum CA-125 blood testing combined with transvaginal ultrasound (TVU), performed every six months.

CA-125 measures a protein produced by ovarian cancer cells. Elevated levels may indicate cancer presence, but false positives occur frequently from benign gynecologic conditions, endometriosis, and menstruation. Transvaginal ultrasound provides direct visualization of ovarian structures, identifying cysts and masses. Combined use of both modalities theoretically improves detection sensitivity. Some centers incorporate supplementary MRI imaging for enhanced visualization, though evidence for MRI benefit in BRCA screening remains limited.

Screening typically continues from age 30-35 until menopause, or earlier if a woman chooses risk-reducing surgery. The recommended six-month interval reflects attempts to detect cancer at earlier stages, though this intense surveillance burden creates substantial psychological cost and anxiety for many carriers.

Screening Effectiveness and Limitations

Despite sophisticated screening protocols, the effectiveness of ovarian cancer surveillance in BRCA carriers remains disappointing. Research in the Journal of Clinical Oncology (2020) shows that screening detects only 50% of early-stage ovarian cancers. Moreover, critically, no mortality benefit has been demonstrated for screening in high-risk women. Most screening-detected cancers are already advanced stage at discovery, suggesting that screening detects cancers that would have presented sympomatically within months.

The high false-positive rate creates substantial morbidity. Many women undergo unnecessary ultrasound follow-ups, repeat CA-125 testing, and potentially unnecessary surgical evaluations based on screening abnormalities. This psychological burden of surveillance—the ongoing anxiety about cancer risk despite negative results, the stress of waiting for repeat testing, the uncertainty of borderline findings—represents a significant quality-of-life cost.

For these reasons, screening should be viewed as a transitional surveillance strategy, providing some reassurance while women plan for definitive prevention through either surgery or chemoprevention. BRCA carriers must understand that screening offers early detection potential, not risk reduction.

Risk-Reducing Surgery (RRSO): Options and Timing

What Is RRSO Surgery?

Risk-reducing salpingo-oophorectomy (RRSO) represents the gold standard for ovarian cancer prevention in BRCA carriers. This bilateral surgical removal of ovaries and fallopian tubes eliminates the tissue from which ovarian and fallopian tube cancers arise. Both ovaries must be removed because cancer risk is bilateral; removing only one ovary provides inadequate protection.

Surgeons typically perform RRSO via laparoscopic approach, minimizing surgical trauma. Recovery generally requires 1-2 weeks before returning to work and 4-6 weeks for complete healing. The procedure is definitive and irreversible, permanently ending egg production and eliminating natural fertility—a critical consideration that affects timing decisions substantially.

RRSO Timing: When to Schedule Surgery

Timing of RRSO represents a critical decision balancing cancer prevention against reproductive and surgical menopause effects. The CDC recommends that BRCA1 carriers consider RRSO between ages 35-40, after childbearing is complete. BRCA2 carriers, facing lower ovarian cancer risk with later median onset, can defer surgery to age 40-45.

However, these are guidelines, not rigid rules. Individual circumstances substantially affect optimal timing. Women with strong family histories showing ovarian cancer diagnoses before age 50 should consider earlier surgery, potentially in their early-to-mid-30s. Conversely, those still planning pregnancies or uncertain about childearing may defer surgery despite meeting the age threshold.

Personal preferences, psychological readiness, and access to specialist care also influence timing. Some women accept increased surveillance risk rather than proceed with surgery. Others prioritize prevention and accept surgical menopause at earlier-than-natural ages. Genetic counseling and discussion with gynecologic oncologists help individualize this profound decision.

RRSO Effectiveness and Residual Risks

RRSO achieves approximately 80% ovarian cancer risk reduction in BRCA carriers, substantially superior to any screening approach. Overall mortality reduction reaches 77%, reflecting the substantial impact of preventing ovarian cancer death. These numbers represent dramatic risk reduction compared to surveillance screening's proven zero percent mortality benefit.

However, RRSO does not completely eliminate ovarian cancer risk. Primary peritoneal cancer (PPC), which develops from peritoneal lining cells rather than ovarian tissue, can still occur after RRSO. Research shows PPC incidence at 2-5% in post-RRSO BRCA carriers over follow-up periods. While PPC occurs at dramatically lower rates than ovarian cancer would, it remains a meaningful residual risk requiring ongoing awareness and surveillance. Post-menopausal women who undergo RRSO typically continue CA-125 monitoring, particularly if symptoms suggestive of cancer emerge.

<!-- IMAGE: Surgery Effectiveness Comparison | Alt: Comparison showing RRSO surgery achieves 80% ovarian cancer risk reduction and 77% mortality reduction, while screening detects only 50% of early-stage cancers with no proven mortality benefit -->

Hormone Replacement Therapy After RRSO

Managing Surgical Menopause

RRSO creates immediate surgical menopause, triggering abrupt hormone withdrawal rather than the gradual transition of natural menopause. This sudden hormonal change causes intense vasomotor symptoms (hot flashes, night sweats), vaginal atrophy with sexual dysfunction, accelerated bone loss, and increased cardiovascular disease risk. The physical symptoms substantially impact quality of life for many women during years following surgery.

Hormone replacement therapy (HRT) effectively manages these post-surgical symptoms. HRT replaces estrogen and progesterone at levels approximating those in premenopausal years, mitigating hot flashes, improving vaginal health, supporting bone density, and reducing cardiovascular disease risk. HRT is appropriate and recommended for BRCA carriers undergoing RRSO, addressing the genuine medical consequences of surgical menopause.

HRT Safety in BRCA Carriers

A critical question for many BRCA carriers concerns whether HRT increases breast cancer risk. According to the American College of Obstetricians and Gynecologists (ACOG, 2023), short-term HRT—typically 5-10 years following RRSO—does NOT significantly increase breast cancer risk in BRCA carriers. This represents an important reassurance, as many women fear that replacing hormones might increase their substantial baseline breast cancer risk.

Current recommendations support HRT use until natural menopause age (approximately 50-51), meaning women undergoing RRSO at age 35-40 would typically take HRT for roughly 10-15 years. The cardiovascular and bone health protection from HRT during this decade substantially outweighs any modest breast cancer risk. Individual risk-benefit discussions should address family history, personal preferences, and menopausal symptom severity.

<!-- IMAGE: HRT Decision Framework | Alt: Visual guide to HRT safety in BRCA carriers showing cardiovascular benefits, bone protection, and symptom management against modest breast cancer risk considerations -->

Chemoprevention: Oral Contraceptives and Other Options

Oral Contraceptives for Ovarian Cancer Prevention

Oral contraceptive pills (OCPs) offer chemoprevention benefits for BRCA carriers through an elegant mechanism: suppression of ovulation. Reducing ovulation frequency decreases cellular division in ovarian epithelium, lowering the probability of malignant transformation. Research in the American Journal of Epidemiology (2022) demonstrates that prolonged OCP use (5+ years) reduces ovarian cancer risk by 40-50% in BRCA carriers.

Notably, the protective benefit persists 15-20 years after discontinuing contraceptives, suggesting durable effects on ovarian tissue. OCPs represent a reversible intervention suitable for BRCA carriers in their reproductive years who have not yet chosen risk-reducing surgery. They are particularly valuable for women deferring surgery or uncertain about surgical menopause.

However, OCPs carry a trade-off: modest increased breast cancer risk. The relative increase is approximately 10-20%, meaning the absolute risk increase is modest but measurable. For women with very high baseline breast cancer risk (particularly BRCA1 carriers), this trade-off may warrant careful consideration. Individual discussions should address family breast cancer history, age, and personal preferences regarding relative ovarian versus breast cancer risk.

Other Preventive Medications

Tamoxifen and raloxifene, selective estrogen receptor modulators, provide breast cancer prevention benefits in some high-risk women. However, their effectiveness for ovarian cancer prevention in BRCA carriers is minimal or absent. NSAIDs show conflicting epidemiologic evidence and insufficient data for routine recommendation in BRCA carriers.

Current evidence demonstrates that risk-reducing surgery remains substantially more effective than any pharmacologic approach for ovarian cancer prevention in BRCA carriers. Medications serve as adjuncts for those deferring surgery or additional protective strategies, not as primary prevention alternatives.

Genetic Testing for BRCA Mutations

Who Should Get Tested?

Genetic testing for BRCA mutations should be offered to women with personal or family history suggesting hereditary cancer risk. Testing criteria include personal history of ovarian cancer at any age, personal history of early-onset breast cancer (before age 45), family history of BRCA-related cancers (ovarian, early-onset breast, pancreatic, or prostate cancer), known BRCA mutation in the family, or Ashkenazi Jewish ancestry with any cancer diagnosis.

Men with breast cancer or family history of BRCA-related cancers should also be tested. Male BRCA carriers face elevated prostate and pancreatic cancer risks, though ovarian cancer concerns primarily affect female carriers and relatives.

Testing Process and Results Interpretation

Modern genetic testing typically employs multi-gene panels examining BRCA1, BRCA2, and 20-30 additional genes associated with hereditary cancer. Alternatively, single-site testing analyzes a specific known family mutation. Panel testing is preferred for families without prior testing, as it identifies mutations beyond BRCA and may reveal unexpected cancer predisposition genes.

Results interpretation requires careful discussion. Pathogenic variants (confirmed cancer-causing mutations) carry clear implications for elevated cancer risk and management recommendations. Variants of uncertain significance (VUS)—found in approximately 15% of tests—have unclear cancer association and typically warrant continued general population screening rather than aggressive surveillance until additional evidence accumulates.

Negative results in high-risk families may simply reflect incomplete genetic knowledge (approximately 5-10% of hereditary cancers involve genes not yet discovered). Negative results do not eliminate cancer risk in someone with strong personal or family history; they only exclude BRCA mutations and reduce but do not eliminate inherited risk.

Genetic Counseling and Insurance Protections

Pre-test genetic counseling should address psychological implications, discrimination risks, inheritance patterns, and insurance protections. Post-test counseling helps interpret results, discusses management options, and initiates cascade testing—offering free or reduced-cost testing to first-degree relatives at 50% risk of carrying the family mutation.

The Genetic Information Nondiscrimination Act (GINA) protects against health insurance discrimination based on genetic testing results. However, life insurance and disability insurance are not protected by GINA; carriers should consider these implications before testing. Testing typically costs $250-400 after insurance, or $200-300 for single-site analysis targeting a known family mutation. Coverage varies by indication and insurance plan.

Decision-Making: Choosing Your Prevention Strategy

Comparing Your Options

Individualized Factors for Decision

The optimal prevention strategy depends on multiple personal factors: age and reproductive plans, family history patterns (particularly age of ovarian cancer diagnoses in relatives), breast cancer risk considerations, personal preferences and risk tolerance, psychological readiness for surgery, financial factors, and access to specialized gynecologic oncology care.

Women planning pregnancies should defer RRSO until childbearing is complete, potentially using OCPs or surveillance during reproductive years. Those with compelling family histories showing ovarian cancers before age 50 may benefit from earlier surgery consideration. Women with extremely high breast cancer risk might weigh slightly modified approaches, though BRCA-related breast cancer prevention (primarily mastectomy) is handled separately.

Fertility, Pregnancy, and Family Planning

Planning Pregnancy Before RRSO

RRSO permanently eliminates natural fertility, making timing critical. All family planning must occur before surgery. Women uncertain about future pregnancies should defer surgery—quality of life and reproductive autonomy matter substantially. Genetic counseling helps address the 50% inheritance risk to offspring, informing reproductive decisions.

Pre-implantation genetic diagnosis (PGD) allows BRCA-carrier couples to create embryos that do not carry the family mutation, preventing transmission of hereditary cancer predisposition. While expensive and requiring IVF, PGD provides option for some families seeking to break the inheritance chain. Other family-building approaches—adoption, fostering, or other reproductive technologies—remain valid alternatives.

Natural Menopause and Long-Term Management

Women who choose RRSO in their 30s face 15-20 years of HRT use (typically until natural menopause around age 50-51). After HRT discontinuation, some women experience recurrent menopausal symptoms requiring symptomatic management without hormone replacement. Long-term surveillance typically continues for primary peritoneal cancer detection, though the interval and intensity depend on individual circumstances and symptom patterns.

Bone health becomes important post-RRSO, with accelerated bone loss during surgical menopause and ongoing monitoring for osteoporosis. Regular exercise, calcium/vitamin D supplementation, and periodic DEXA scanning support skeletal health. Sexual dysfunction may persist post-menopausal, sometimes manageable with vaginal estrogen or other interventions even after systemic HRT discontinuation.

Personalized Strategies Based on Your BRCA Risk

Step-by-Step Decision Guide

The path to preventing ovarian cancer in BRCA carriers involves sequential steps: First, confirm BRCA1 vs. BRCA2 status (or clarify negative results with strong family history); Second, assess your family history pattern—particularly age of ovarian cancer diagnoses and other cancer types; Third, evaluate your reproductive plans and timeline, as this dramatically influences prevention strategy choices; Fourth, consult with a genetic counselor and gynecologic oncologist to discuss options comprehensively; Fifth, weigh screening versus surgery versus medication strategies based on personal factors; Sixth, implement your chosen strategy with appropriate follow-up; Finally, reassess periodically as circumstances change.

This methodical approach replaces rushing into decisions. Women benefit from thorough counseling, time to process implications, and discussion with multidisciplinary teams including genetic counselors, gynecologic oncologists, medical oncologists, and mental health professionals.

When to Seek Specialist Care

Genetic counselors provide comprehensive pre-test and post-test counseling, family history assessment, and psychological support. Gynecologic oncologists specialize in RRSO timing, surgical technique, and ovarian cancer prevention strategies. Medical oncologists contribute expertise on medication options and surveillance protocols. Breast surgeons coordinate care when addressing both breast and ovarian cancer prevention. Patient advocacy organizations like FORCE (Facing Our Risk of Cancer Empowered) provide peer support and educational resources.

FAQ: BRCA and Ovarian Cancer Risk

Q: What is ovarian cancer risk in BRCA1 and BRCA2 carriers?

BRCA1 carriers face a 39-44% lifetime ovarian cancer risk by age 80, with median diagnosis around age 54. BRCA2 carriers have 11-17% lifetime risk with median diagnosis closer to age 62. These risks vastly exceed the 1.4% risk in the general population. This dramatic elevation explains why BRCA carriers require specialized screening and prevention strategies.

Q: What are the screening options for BRCA carriers?

The National Comprehensive Cancer Network recommends CA-125 blood testing and transvaginal ultrasound every six months starting at age 30-35. Some centers add supplementary MRI imaging. However, importantly, screening detects only 50% of early-stage cancers and has not been shown to improve mortality—it provides early detection potential, not risk reduction.

Q: Can risk-reducing surgery (RRSO) completely eliminate ovarian cancer risk?

RRSO reduces ovarian cancer risk by approximately 80% and decreases overall mortality by 77%—dramatic protection. However, it does not completely eliminate risk. Primary peritoneal cancer can still develop in 2-5% of RRSO patients. Despite this residual risk, RRSO represents the most effective prevention option available today.

Q: When should BRCA1 and BRCA2 carriers have RRSO?

BRCA1 carriers should typically consider RRSO between ages 35-40, after completing childbearing. BRCA2 carriers can defer to ages 40-45 due to later cancer onset. Timing should be individualized based on family history, reproductive plans, and psychological readiness. Earlier surgery is reasonable if relatives developed ovarian cancer before age 50.

Q: Do oral contraceptives reduce ovarian cancer risk in BRCA carriers?

Yes—oral contraceptives reduce ovarian cancer risk by 40-50% with five or more years of continuous use. The benefit persists 15-20 years after discontinuation. However, OCPs may modestly increase breast cancer risk (10-20% relative increase), requiring individual risk-benefit discussion, particularly in BRCA1 carriers.

Q: What happens after RRSO surgery—do you need hormone replacement therapy?

Hormone replacement therapy is recommended for BRCA carriers undergoing RRSO until natural menopause age (approximately 50-51). HRT mitigates cardiovascular disease risk, osteoporosis, and menopausal symptoms from surgical menopause. Importantly, short-term HRT (5-10 years) does not significantly increase breast cancer risk in BRCA carriers, making HRT safe and appropriate.

Q: Can women with BRCA mutations still have children after preventive surgery?

RRSO permanently eliminates egg production, eliminating natural fertility. All family planning must occur before surgery. Pre-implantation genetic diagnosis (PGD) allows BRCA-carrier couples to select BRCA-mutation-free embryos, preventing inheritance. Alternative family-building options include adoption and surrogacy.

Q: How is BRCA-related ovarian cancer different from sporadic ovarian cancer?

BRCA-associated cancers develop 10-15 years earlier than sporadic cancers. They predominantly manifest as high-grade serous histology. Crucially, BRCA cancers demonstrate exceptional sensitivity to platinum chemotherapy and PARP inhibitors, providing treatment advantages. Five-year survival with treatment is 40-50%—improved compared to sporadic ovarian cancer.

Q: What is primary peritoneal cancer and how does it relate to BRCA ovarian cancer risk?

Primary peritoneal cancer develops from peritoneal lining cells rather than ovarian tissue. It can occur even after RRSO removes the ovaries. PPC occurs in approximately 2-5% of RRSO patients and can be detected similarly to ovarian cancer. It has comparable treatment response to ovarian cancer and carries worse prognosis if undetected.

Q: What does genetic counseling for BRCA involve?

Pre-test counseling addresses implications, risks, benefits, and insurance protections. Result interpretation explains pathogenic variants versus variants of uncertain significance. Post-test counseling discusses management options, cascade testing (offering testing to relatives), and ongoing support. Genetic counselors provide psychological support throughout this complex decision-making journey.

Q: What are variants of uncertain significance (VUS) and how should they be handled?

Variants of uncertain significance are DNA changes found in approximately 15% of BRCA tests that have unclear cancer association. They require further research for proper classification. Until reclassified, individuals with VUS typically follow general population screening recommendations. VUS results may be reclassified as pathogenic or benign as scientific evidence accumulates.

Q: Is genetic testing covered by insurance and what about discrimination?

Testing typically costs $250-400 after insurance, or $200-300 for single-site analysis. Insurance usually covers testing for ovarian cancer history or known mutations in the family. The Genetic Information Nondiscrimination Act (GINA) protects against health insurance discrimination but does not protect life or disability insurance. Carriers should understand these limitations before testing.

Conclusion

BRCA1 and BRCA2 mutations create substantially elevated ovarian cancer risk requiring individualized, multifaceted management. The central decisions involve choosing among surveillance screening, risk-reducing surgery, chemoprevention medications, or combination approaches—each with distinct benefits, risks, and implications for fertility and long-term health.

Current evidence strongly supports risk-reducing salpingo-oophorectomy as the most effective ovarian cancer prevention (80% risk reduction, 77% mortality reduction), though this carries permanent effects on fertility and requires hormone replacement therapy to manage surgical menopause. For those deferring surgery, oral contraceptives provide modest protection while surveillance offers limited effectiveness but some reassurance.

The optimal strategy depends on individual factors: age, fertility desires, family history patterns, personal risk tolerance, access to specialized care, and psychological readiness. Genetic counseling before and after testing is essential, and ongoing consultation with multidisciplinary specialists ensures management aligns with current evidence and personal circumstances.

Women with BRCA mutations should feel empowered rather than overwhelmed by their diagnosis. Multiple effective prevention options exist, and healthcare providers specialized in hereditary cancer care are available to guide decision-making. With informed decision-making and appropriate monitoring, BRCA carriers can substantially reduce their ovarian cancer risk and maintain quality of life.

📋 Educational Content Disclaimer

This article provides educational information about genetic variants and is not intended as medical advice. Always consult qualified healthcare providers for personalized medical guidance. Genetic information should be interpreted alongside medical history and professional assessment.